Enhanced Screening for Hepatitis D in the USA: Overcoming the Delta Blues.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
   Article
2. Current prevalence of hepatitis delta diagnosis in Valencia, Spain.Scientific reports · 2025
   Article
3. Diagnosis and Management of Hepatitis Delta Virus Infection.Digestive diseases and sciences · 2023
   Review
4. An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D.Cureus · 2023
   Review

Corrections and comments

• Comment on
  High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.2021

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as